Alkermes (FRA:8AK) Cyclically Adjusted Revenue per Share: €7.74 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8AK Alkermes PLC FRA:8AK
51 GF Score
Price €42.15
GF Value €27.37
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Alkermes Cyclically Adjusted Revenue per Share?

Alkermes FRA:8AK +1.57% 51 Cyclically Adjusted Revenue per Share is €7.74 as of Jun. 2026. GuruFocus rates FRA:8AK with a GF Score™ of 51/100 and a GF Value™ of €27.37 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Alkermes's adjusted revenue per share for the three months ended in Jun. 2026 was €2.482. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €7.74 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Alkermes's average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Alkermes was 19.40% per year. The lowest was 4.20% per year. And the median was 11.50% per year.

As of today (2026-08-11), Alkermes's current stock price is €42.15. Alkermes's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €7.74. Alkermes's Cyclically Adjusted PS Ratio of today is 5.45.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Alkermes was 16.57. The lowest was 2.54. And the median was 4.01.


Alkermes  (FRA:8AK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Alkermes's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=42.15/7.74
=5.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Alkermes was 16.57. The lowest was 2.54. And the median was 4.01.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Alkermes Cyclically Adjusted Revenue per Share Related Terms


Alkermes Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Alkermes's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkermes Cyclically Adjusted Revenue per Share Chart

Alkermes Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.31 6.12 6.57 7.61 7.06

Alkermes Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.90 6.68 7.06 6.38 7.74

FRA:8AK vs LQDA, LNTH, HIMS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkermes Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Alkermes's Cyclically Adjusted PS Ratio falls into.


FRA:8AK
51GF Score
Alkermes PLC FRA:8AK
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alkermes Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alkermes's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.482/128.6700*128.6700
=2.482

Current CPI (Jun. 2026) = 128.6700.

Alkermes Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.059 100.274 1.359
201612 1.330 99.676 1.717
201703 1.174 100.374 1.505
201706 1.270 100.673 1.623
201709 1.187 100.474 1.520
201712 1.512 100.075 1.944
201803 1.182 100.573 1.512
201806 1.681 101.072 2.140
201809 1.372 101.371 1.741
201812 1.785 100.773 2.279
201903 1.263 101.670 1.598
201906 1.578 102.168 1.987
201909 1.474 102.268 1.855
201912 2.356 102.068 2.970
202003 1.409 102.367 1.771
202006 1.383 101.769 1.749
202009 1.415 101.072 1.801
202012 1.446 101.072 1.841
202103 1.323 102.367 1.663
202106 1.538 103.364 1.915
202109 1.549 104.859 1.901
202112 1.622 106.653 1.957
202203 1.557 109.245 1.834
202206 1.595 112.779 1.820
202209 1.551 113.504 1.758
202212 1.750 115.436 1.951
202303 1.627 117.609 1.780
202306 3.322 119.662 3.572
202309 2.076 120.749 2.212
202312 2.074 120.749 2.210
202403 1.863 120.990 1.981
202406 2.169 122.318 2.282
202409 2.040 121.594 2.159
202412 2.471 122.439 2.597
202503 1.680 123.405 1.752
202506 2.012 124.492 2.080
202509 1.993 124.810 2.055
202512 1.936 125.770 1.981
202603 2.045 127.830 2.058
202606 2.482 128.670 2.482

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €7.74 mean?
Alkermes (FRA:8AK) has a Cyclically Adjusted Revenue per Share of €7.74 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Alkermes and its competitors.
Is Alkermes' Cyclically Adjusted Revenue per Share too high?
Alkermes' current Cyclically Adjusted Revenue per Share is €7.74. Overall, Alkermes has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alkermes' Cyclically Adjusted Revenue per Share compare to LQDA and LNTH?
Alkermes' Cyclically Adjusted Revenue per Share of €7.74 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Alkermes and its competitors. Alkermes's current Cyclically Adjusted Revenue per Share is €7.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkermes stock overvalued right now?
Based on GuruFocus' analysis, Alkermes (FRA:8AK) is currently considered Significantly Overvalued. The stock's GF Value™ is €27.37, compared to a current price of €42.15 — trading 54% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €7.74. Alkermes' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Alkermes (FRA:8AK), the current Cyclically Adjusted Revenue per Share is €7.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alkermes (FRA:8AK) Overvalued in 2026?

Based on GuruFocus' analysis, Alkermes stock appears to be overvalued. The current stock price of €42.15 is trading 54% above its estimated GF Value™ of €27.37. GuruFocus considers Alkermes to be Significantly Overvalued.

Key valuation signals for FRA:8AK:

  • Cyclically Adjusted Revenue per Share: €7.74
  • GF Value™: €27.37 vs. price of €42.15 (54% above fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the FRA:8AK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alkermes Business Description

Other Exchanges ALKS:USA
Address 1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
51GF Score

Get the complete analysis for FRA:8AK

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€42.15
Price
€27.37
GF Value